Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2000

01-11-2000 | ORIGINAL ARTICLE

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A

Authors: James W. Raschko, Timothy W. Synold, Warren Chow, Paul Coluzzi, Victor Hamasaki, Lucille A. Leong, Kim A. Margolin, Robert J. Morgan, Stephen I. Shibata, George Somlo, Merry L. Tetef, Yun Yen, Anna ter Veer, James H. Doroshow

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2000

Login to get access
Metadata
Title
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A
Authors
James W. Raschko
Timothy W. Synold
Warren Chow
Paul Coluzzi
Victor Hamasaki
Lucille A. Leong
Kim A. Margolin
Robert J. Morgan
Stephen I. Shibata
George Somlo
Merry L. Tetef
Yun Yen
Anna ter Veer
James H. Doroshow
Publication date
01-11-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800000142

Other articles of this Issue 5/2000

Cancer Chemotherapy and Pharmacology 5/2000 Go to the issue

ORIGINAL ARTICLE

Phase I study of liposomal annamycin

ORIGINAL ARTICLE

Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy

ORIGINAL ARTICLE

Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer

ORIGINAL ARTICLE

Population pharmacokinetics of topotecan: intraindividual variability in total drug

ORIGINAL ARTICLE

A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies

ORIGINAL ARTICLE

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits